Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVAC-1 in advanced solid tumors
NCT02301754Phase 1Completed
- Sponsor
- Invectys
- Start
- Nov 2014
- Primary completion
- Feb 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of INVAC-1 in solid tumor, sponsored by Invectys. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Nov 2014; status: completed.
02
Drugs
INVAC-1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02301754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301754.